Search

Your search keyword '"Raymon, Heather K."' showing total 106 results
Start Over Author "Raymon, Heather K."
106 results on '"Raymon, Heather K."'

1. Structure-based optimization of aminothiadiazole inhibitors of AKT

Author

Mortensen, Deborah S., Hegde, Sayee G., Perrin-Ninkovic, Sophie M., Bahmanyar, Sogole, McCarrick, Meg, Harris, Roy, Hilgraf, Robert, Lee, Branden G. S., McKie, Jeff, Nadolny, Lisa, Sapienza, John, Collette, Alice, Cox, Sarah, Gamez, James C., Hensel, Jennifer L., Hua, Xuequn Helen, Leisten, Jim, Raymon, Heather K., Tran, Tam, and Narla, Rama Krishna

Published
2023
Full Text
View/download PDF

3. Data from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

Author

Mortensen, Deborah S., primary, Fultz, Kimberly E., primary, Xu, Shuichan, primary, Xu, Weiming, primary, Packard, Garrick, primary, Khambatta, Godrej, primary, Gamez, James C., primary, Leisten, Jim, primary, Zhao, Jingjing, primary, Apuy, Julius, primary, Ghoreishi, Kamran, primary, Hickman, Matt, primary, Narla, Rama Krishna, primary, Bissonette, Rene, primary, Richardson, Samantha, primary, Peng, Sophie X., primary, Perrin-Ninkovic, Sophie, primary, Tran, Tam, primary, Shi, Tao, primary, Yang, Wen Qing, primary, Tong, Zeen, primary, Cathers, Brian E., primary, Moghaddam, Mehran F., primary, Canan, Stacie S., primary, Worland, Peter, primary, Sankar, Sabita, primary, and Raymon, Heather K., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figures S1-S3, Tables S1-S7 from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

Author

Mortensen, Deborah S., primary, Fultz, Kimberly E., primary, Xu, Shuichan, primary, Xu, Weiming, primary, Packard, Garrick, primary, Khambatta, Godrej, primary, Gamez, James C., primary, Leisten, Jim, primary, Zhao, Jingjing, primary, Apuy, Julius, primary, Ghoreishi, Kamran, primary, Hickman, Matt, primary, Narla, Rama Krishna, primary, Bissonette, Rene, primary, Richardson, Samantha, primary, Peng, Sophie X., primary, Perrin-Ninkovic, Sophie, primary, Tran, Tam, primary, Shi, Tao, primary, Yang, Wen Qing, primary, Tong, Zeen, primary, Cathers, Brian E., primary, Moghaddam, Mehran F., primary, Canan, Stacie S., primary, Worland, Peter, primary, Sankar, Sabita, primary, and Raymon, Heather K., primary

Published
2023
Full Text
View/download PDF

5. Supplemental Methods; Supplemental Tables S1-S7; and Supplemental Figures S1-S6 from Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Author

Zhu, Dan, primary, Xu, Shuichan, primary, Deyanat-Yazdi, Gordafaried, primary, Peng, Sophie X., primary, Barnes, Leo A., primary, Narla, Rama Krishna, primary, Tran, Tam, primary, Mikolon, David, primary, Ning, Yuhong, primary, Shi, Tao, primary, Jiang, Ning, primary, Raymon, Heather K., primary, Riggs, Jennifer R., primary, and Boylan, John F., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 5 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Data from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, primary, Goodwin, Jonathan F., primary, Raymon, Heather K., primary, McCue, Peter A., primary, Shafi, Ayesha A., primary, Leiby, Benjamin E., primary, de Leeuw, Renée, primary, Kothari, Vishal, primary, McCann, Jennifer J., primary, Mandigo, Amy C., primary, Chand, Saswati N., primary, Schiewer, Matthew J., primary, Brand, Lucas J., primary, Vasilevskaya, Irina, primary, Gordon, Nicolas, primary, Laufer, Talya S., primary, Gomella, Leonard G., primary, Lallas, Costas D., primary, Trabulsi, Edouard J., primary, Feng, Felix Y., primary, Filvaroff, Ellen H., primary, Hege, Kristin, primary, Rathkopf, Dana, primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure Legend from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

12. Data from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Tables from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, primary, Goodwin, Jonathan F., primary, Raymon, Heather K., primary, McCue, Peter A., primary, Shafi, Ayesha A., primary, Leiby, Benjamin E., primary, de Leeuw, Renée, primary, Kothari, Vishal, primary, McCann, Jennifer J., primary, Mandigo, Amy C., primary, Chand, Saswati N., primary, Schiewer, Matthew J., primary, Brand, Lucas J., primary, Vasilevskaya, Irina, primary, Gordon, Nicolas, primary, Laufer, Talya S., primary, Gomella, Leonard G., primary, Lallas, Costas D., primary, Trabulsi, Edouard J., primary, Feng, Felix Y., primary, Filvaroff, Ellen H., primary, Hege, Kristin, primary, Rathkopf, Dana, primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

15. Data from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, primary, Goodwin, Jonathan F., primary, Raymon, Heather K., primary, McCue, Peter A., primary, Shafi, Ayesha A., primary, Leiby, Benjamin E., primary, de Leeuw, Renée, primary, Kothari, Vishal, primary, McCann, Jennifer J., primary, Mandigo, Amy C., primary, Chand, Saswati N., primary, Schiewer, Matthew J., primary, Brand, Lucas J., primary, Vasilevskaya, Irina, primary, Gordon, Nicolas, primary, Laufer, Talya S., primary, Gomella, Leonard G., primary, Lallas, Costas D., primary, Trabulsi, Edouard J., primary, Feng, Felix Y., primary, Filvaroff, Ellen H., primary, Hege, Kristin, primary, Rathkopf, Dana, primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 6 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, primary, Guo, Deliang, primary, Matsutani, Tomoo, primary, Masui, Kenta, primary, Ikegami, Shiro, primary, Yang, Huijun, primary, Nathanson, David, primary, Villa, Genaro R., primary, Shackelford, David, primary, Zhu, Shaojun, primary, Tanaka, Kazuhiro, primary, Babic, Ivan, primary, Akhavan, David, primary, Lin, Kelly, primary, Assuncao, Alvaro, primary, Gu, Yuchao, primary, Bonetti, Bruno, primary, Mortensen, Deborah S., primary, Xu, Shuichan, primary, Raymon, Heather K., primary, Cavenee, Webster K., primary, Furnari, Frank B., primary, James, C. David, primary, Kroemer, Guido, primary, Heath, James R., primary, Hege, Kristen, primary, Chopra, Rajesh, primary, Cloughesy, Timothy F., primary, and Mischel, Paul S., primary

Published
2023
Full Text
View/download PDF

21. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Author

Narla, Rama Krishna, primary, Modi, Hardik, additional, Bauer, Daniel, additional, Abbasian, Mahan, additional, Leisten, Jim, additional, Piccotti, Joseph R., additional, Kopytek, Stephan, additional, Eckelman, Brendan P., additional, Deveraux, Quinn, additional, Timmer, John, additional, Zhu, Dan, additional, Wong, Lilly, additional, Escoubet, Laure, additional, Raymon, Heather K., additional, and Hariharan, Kandasamy, additional

Published
2021
Full Text
View/download PDF

24. Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, additional, Goodwin, Jonathan F., additional, Raymon, Heather K., additional, McCue, Peter A., additional, Shafi, Ayesha A., additional, Leiby, Benjamin E., additional, de Leeuw, Renée, additional, Kothari, Vishal, additional, McCann, Jennifer J., additional, Mandigo, Amy C., additional, Chand, Saswati N., additional, Schiewer, Matthew J., additional, Brand, Lucas J., additional, Vasilevskaya, Irina, additional, Gordon, Nicolas, additional, Laufer, Talya S., additional, Gomella, Leonard G., additional, Lallas, Costas D., additional, Trabulsi, Edouard J., additional, Feng, Felix Y., additional, Filvaroff, Ellen H., additional, Hege, Kristin, additional, Rathkopf, Dana, additional, and Knudsen, Karen E., additional

Published
2019
Full Text
View/download PDF

25. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Author

Zhu, Dan, primary, Xu, Shuichan, additional, Deyanat-Yazdi, Gordafaried, additional, Peng, Sophie X., additional, Barnes, Leo A., additional, Narla, Rama Krishna, additional, Tran, Tam, additional, Mikolon, David, additional, Ning, Yuhong, additional, Shi, Tao, additional, Jiang, Ning, additional, Raymon, Heather K., additional, Riggs, Jennifer R., additional, and Boylan, John F., additional

Published
2018
Full Text
View/download PDF

27. Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo

Author

Narla, Rama Krishna, primary, Modi, Hardik, additional, Wong, Lilly, additional, Abassian, Mahan, additional, Bauer, Daniel, additional, Desai, Pragnya, additional, Gaffney, Bonny, additional, Jackson, Pilgrim, additional, Leisten, Jim, additional, Liu, Jing, additional, Lopez-Girona, Antonia, additional, Romero, Maria, additional, Yang, WenQing, additional, Eckelman, Brendan P., additional, Deveraux, Quinn, additional, Phillips, Laurie, additional, Raymon, Heather K., additional, Escoubet, Laure, additional, Boylan, John, additional, and Hariharan, Kandasamy, additional

Published
2017
Full Text
View/download PDF

28. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

Author

Mortensen, Deborah S., primary, Perrin-Ninkovic, Sophie M., additional, Shevlin, Graziella, additional, Elsner, Jan, additional, Zhao, Jingjing, additional, Whitefield, Brandon, additional, Tehrani, Lida, additional, Sapienza, John, additional, Riggs, Jennifer R., additional, Parnes, Jason S., additional, Papa, Patrick, additional, Packard, Garrick, additional, Lee, Branden G.S., additional, Harris, Roy, additional, Correa, Matthew, additional, Bahmanyar, Sogole, additional, Richardson, Samantha J., additional, Peng, Sophie X., additional, Leisten, Jim, additional, Khambatta, Godrej, additional, Hickman, Matt, additional, Gamez, James C., additional, Bisonette, René R., additional, Apuy, Julius, additional, Cathers, Brian E., additional, Canan, Stacie S., additional, Moghaddam, Mehran F., additional, Raymon, Heather K., additional, Worland, Peter, additional, Narla, Rama Krishna, additional, Fultz, Kimberly E., additional, and Sankar, Sabita, additional

Published
2015
Full Text
View/download PDF

29. Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223

Author

Mortensen, Deborah S., primary, Perrin-Ninkovic, Sophie M., additional, Shevlin, Graziella, additional, Zhao, Jingjing, additional, Packard, Garrick, additional, Bahmanyar, Sogole, additional, Correa, Matthew, additional, Elsner, Jan, additional, Harris, Roy, additional, Lee, Branden G. S., additional, Papa, Patrick, additional, Parnes, Jason S., additional, Riggs, Jennifer R., additional, Sapienza, John, additional, Tehrani, Lida, additional, Whitefield, Brandon, additional, Apuy, Julius, additional, Bisonette, René R., additional, Gamez, James C., additional, Hickman, Matt, additional, Khambatta, Godrej, additional, Leisten, Jim, additional, Peng, Sophie X., additional, Richardson, Samantha J., additional, Cathers, Brian E., additional, Canan, Stacie S., additional, Moghaddam, Mehran F., additional, Raymon, Heather K., additional, Worland, Peter, additional, Narla, Rama Krishna, additional, Fultz, Kimberly E., additional, and Sankar, Sabita, additional

Published
2015
Full Text
View/download PDF

30. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization

Author

Mortensen, Deborah S., primary, Fultz, Kimberly E., additional, Xu, Shuichan, additional, Xu, Weiming, additional, Packard, Garrick, additional, Khambatta, Godrej, additional, Gamez, James C., additional, Leisten, Jim, additional, Zhao, Jingjing, additional, Apuy, Julius, additional, Ghoreishi, Kamran, additional, Hickman, Matt, additional, Narla, Rama Krishna, additional, Bissonette, Rene, additional, Richardson, Samantha, additional, Peng, Sophie X., additional, Perrin-Ninkovic, Sophie, additional, Tran, Tam, additional, Shi, Tao, additional, Yang, Wen Qing, additional, Tong, Zeen, additional, Cathers, Brian E., additional, Moghaddam, Mehran F., additional, Canan, Stacie S., additional, Worland, Peter, additional, Sankar, Sabita, additional, and Raymon, Heather K., additional

Published
2015
Full Text
View/download PDF

32. CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Author

Hagner, Patrick, primary, Wang, Maria, additional, Couto, Suzana, additional, Breider, Mike, additional, Fontanillo, Celia, additional, Trotter, Matthew, additional, Bjorklund, Chad C, additional, Havens, Courtney G., additional, Raymon, Heather K, additional, Narla, Rama Krishna, additional, Barnes, Leo, additional, Waldman, Michelle, additional, Daniel, Tom, additional, Klippel, Anke, additional, Pourdehnad, Michael, additional, Thakurta, Anjan, additional, Chopra, Rajesh, additional, and Gandhi, Anita K., additional

Published
2014
Full Text
View/download PDF

35. The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Author

Rychak, Emily, primary, Mendy, Derek, additional, Miller, Karen, additional, Leisten, Jim, additional, Narla, Rama Krishna, additional, Raymon, Heather K, additional, Chopra, Rajesh, additional, and Lopez-Girona, Antonia, additional

Published
2013
Full Text
View/download PDF

37. The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

Author

Gini, Beatrice, primary, Zanca, Ciro, additional, Guo, Deliang, additional, Matsutani, Tomoo, additional, Masui, Kenta, additional, Ikegami, Shiro, additional, Yang, Huijun, additional, Nathanson, David, additional, Villa, Genaro R., additional, Shackelford, David, additional, Zhu, Shaojun, additional, Tanaka, Kazuhiro, additional, Babic, Ivan, additional, Akhavan, David, additional, Lin, Kelly, additional, Assuncao, Alvaro, additional, Gu, Yuchao, additional, Bonetti, Bruno, additional, Mortensen, Deborah S., additional, Xu, Shuichan, additional, Raymon, Heather K., additional, Cavenee, Webster K., additional, Furnari, Frank B., additional, James, C. David, additional, Kroemer, Guido, additional, Heath, James R., additional, Hege, Kristen, additional, Chopra, Rajesh, additional, Cloughesy, Timothy F., additional, and Mischel, Paul S., additional

Published
2013
Full Text
View/download PDF

38. Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Author

Carrancio, Soraya, primary, Markovics, Jennifer A, additional, Wong, Piu, additional, Leisten, Jim, additional, Groza, Matthew C, additional, Raymon, Heather K, additional, Heise, Carla, additional, Chopra, Rajesh, additional, Daniel, Tom O, additional, and Sung, Victoria, additional

Published
2012
Full Text
View/download PDF

39. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.

Author

Lotharius, Julie, Barg, Sebastian, Wiekop, Pia, Lundberg, Cecilia, Raymon, Heather K, Brundin, Patrik, Lotharius, Julie, Barg, Sebastian, Wiekop, Pia, Lundberg, Cecilia, Raymon, Heather K, and Brundin, Patrik

Abstract

Mutations in alpha-synuclein have been linked to rare, autosomal dominant forms of Parkinson's disease. Despite its ubiquitous expression, mutant alpha-synuclein primarily leads to the loss of dopamine-producing neurons in the substantia nigra. alpha-Synuclein is a presynaptic nerve terminal protein of unknown function, although several studies suggest it is important for synaptic plasticity and maintenance. The present study utilized a new human mesencephalic cell line, MESC2.10, to study the effect of A53T mutant alpha-synuclein on dopamine homeostasis. In addition to expressing markers of mature dopamine neurons, differentiated MESC2.10 cells are electrically active, produce dopamine, and express wild-type human alpha-synuclein. Lentivirus-induced overexpression of A53T mutant alpha-synuclein in differentiated MESC2.10 cells resulted in down-regulation of the vesicular dopamine transporter (VMAT2), decreased potassium-induced and increased amphetamine-induced dopamine release, enhanced cytoplasmic dopamine immunofluorescence, and increased intracellular levels of superoxide. These results suggest that mutant alpha-synuclein leads to an impairment in vesicular dopamine storage and consequent accumulation of dopamine in the cytosol, a pathogenic mechanism that underlies the toxicity of the psychostimulant amphetamine and the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium. Interestingly, cells expressing A53T mutant alpha-synuclein were resistant to amphetamine-induced toxicity. Because extravesicular, cytoplasmic dopamine can be easily oxidized into reactive oxygen species and other toxic metabolites, mutations in alpha-synuclein might lead to Parkinson's disease by triggering protracted, low grade dopamine toxicity resulting in terminal degeneration and ultimately cell death.

Published
2002
Full Text
View/download PDF

40. The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-α Production with Antitumor Activity

Author

Zhang, Ling-Hua, primary, Wu, Lei, additional, Raymon, Heather K., additional, Chen, Roger S., additional, Corral, Laura, additional, Shirley, Michael A., additional, Krishna Narla, Rama, additional, Gamez, Jim, additional, Muller, George W., additional, Stirling, David I., additional, Bartlett, J. Blake, additional, Schafer, Peter H., additional, and Payvandi, Faribourz, additional

Published
2006
Full Text
View/download PDF

50. The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In VitroModels Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide

Author

Rychak, Emily, Mendy, Derek, Miller, Karen, Leisten, Jim, Narla, Rama Krishna, Raymon, Heather K, Chopra, Rajesh, and Lopez-Girona, Antonia

Abstract

Over expression of the PI3 kinase/mTOR/AKT pathway has been well documented in MM patient biopsies and human MM cell lines, suggesting this pathway plays a key role in the survival and proliferation of malignant plasma cells. Rapamycin and the rapalogs are allosteric inhibitors of the mTORC1 complex (consisting of mTOR, raptor, mLST8 and PRAS40), inducing mainly cytostatic effects but not cell death. Inhibition of mTORC1 prevents a negative feedback loop to the mTORC2 complex (consisting of mTOR, Rictor, mLST8 and Sin 1) leading to the phosphorylation of AKT. Phosphorylated AKT is a key inducer of anti-apoptosis mechanisms and cell cycle progression, which may explain the limited results of the rapalogs in the clinic. Recently developed mTOR kinase inhibitors (i.e., CC-223) target both mTORC1 and mTORC2 complexes in order to inhibit tumor growth and importantly, induce cell death. Here we evaluate the effects of CC-223 on a panel of MM cell lines, in combination with current standard of care agents in MM (the corticosteroid, dexamethasone [DEX] and the IMiD® immunomodulatory drugs, lenalidomide [LEN] and pomalidomide [POM]), as well as in the context of LEN resistance.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results